Loading...
$ 1,000
Type: Cyclic peptide
Composition: Melanocortin receptor agonist
Structure: Modified Melanotan II derivative
Key Feature: Cyclic lactam peptide backbone
PT-141, also known as Bremelanotide, is a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH). Unlike other compounds that target the vascular system (such as PDE5 inhibitors), PT-141 acts on the central nervous system to influence sexual arousal. It has been widely studied in the context of hypoactive sexual desire disorder (HSDD), as well as for general libido enhancement in both male and female animal models.
PT-141 primarily targets melanocortin receptors, particularly MC3R and MC4R, in the brain. This central action is believed to increase sexual desire and arousal by modulating dopamine-related pathways. Unlike sildenafil and similar compounds that act peripherally by increasing blood flow, PT-141 initiates arousal by stimulating neurological activity related to sexual behavior, which makes it particularly valuable in behavioral and neuroendocrine research.
In research and early clinical studies, PT-141 has demonstrated good tolerability. Reported side effects in laboratory models include transient nausea, flushing, and occasional headache. Because it acts centrally, it does not appear to significantly affect blood pressure or cardiovascular function. However, it remains a research chemical and is not approved for unregulated or personal use outside of clinical trials.
PT-141 is a unique melanocortin receptor agonist that offers researchers a new avenue for studying the neurological and behavioral regulation of sexual function and desire. Its ability to directly activate central pathways involved in libido sets it apart from traditional vasodilatory treatments. PT-141 is for laboratory research use only and is not for human consumption.




(936) 931 8152
Monday – Friday 9AM – 4PM CST
Shipping Days
Mailing Address
Sign up to stay informed about our latest product releases, exclusive discounts, and in-depth product insights—delivered straight to your inbox